Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025
COVID-19 vaccination provides additional protection against severe COVID-19-associated illness and death. Since September 2023, 2023-2024 Formula monovalent XBB.1-strain COVID-19 vaccines have been recommended for use in the United States for all persons aged ≥6 months. However, SARS-CoV-2 continues to evolve, and since winter 2023-2024, Omicron JN.1 lineage strains of SARS-CoV-2, including the JN.1 strain and the KP.2 strain, have been widely circulating in the United States. Further, COVID-19 vaccine effectiveness is known to wane. On June 27, 2024, the Advisory Committee on Immunization Practices (ACIP) recommended 2024-2025 COVID-19 vaccination with a Food and Drug Administration (FDA)-approved or authorized vaccine for all persons aged ≥6 months. On August 22, 2024, FDA approved the 2024-2025 COVID-19 vaccines by Moderna and Pfizer-BioNTech (based on the KP.2 strain) for use in persons aged ≥12 years and authorized these vaccines for use in children aged 6 months-11 years under Emergency Use Authorization (EUA). On August 30, 2024, FDA authorized 2024-2025 COVID-19 vaccine by Novavax (based on the JN.1 strain) for use in persons aged ≥12 years under EUA. ACIP will continue to evaluate new evidence as it becomes available and will update recommendations as needed.
Authors
- Megan Wallace (ORCID: https://orcid.org/0000-0003-4331-5785)
- Matthew F. Daley (ORCID: https://orcid.org/0000-0003-1309-4096)
- Danielle Moulia
- Oliver Brooks
- Ruth Link‐Gelles (ORCID: https://orcid.org/0000-0002-9617-806X)
- Katherine E. Fleming-Dutra (ORCID: https://orcid.org/0000-0002-4862-0650)
- Monica Godfrey
- Fiona P. Havers (ORCID: https://orcid.org/0000-0001-9873-6195)
- Lauren Roper (ORCID: https://orcid.org/0000-0001-6504-9735)
- H. Keipp Talbot (ORCID: https://orcid.org/0000-0003-0141-1760)
- Lakshmi Panagiotakopoulos (ORCID: https://orcid.org/0000-0001-5216-0936)
- Shannon Stokley
- Robert Schechter
- Christopher A. Taylor (ORCID: https://orcid.org/0000-0002-0937-5461)
Publication Details
- Journal
- MMWR Morbidity and Mortality Weekly Report
- Published
- 2024-09-10
- DOI
- https://doi.org/10.15585/mmwr.mm7337e2
- Citations
- 68
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 26.45
Funders
- U.S. Department of Defense
- U.S. Department of Health and Human Services
- Pfizer
- Yale University
- Council of State and Territorial Epidemiologists
- Kaiser Permanente
- Brown University
- Vanderbilt University
- Emory University
- George Washington University
- University of Washington
- Johns Hopkins University
- Drexel University
- American Pharmacists Association
- Public Health Agency of Canada
- Marshfield Clinic Research Institute
- Vanderbilt University Medical Center
- Kaiser Permanente Washington Health Research Institute
- Novavax
- Northwell Health
- Moderna
- Public Health Agency
- National Institutes of Health
- Centers for Disease Control and Prevention
- Office of the Assistant Secretary for Health
- School of Medicine, Stanford University
- University of California, Los Angeles
- College of Medicine, Drexel University
- Biomedical Advanced Research and Development Authority